The European Oncology Nursing Society has launched a breakthrough cancer pain initiative to improve patient outcomes in palliative care. The survey aims to identify knowledge gaps and provide insights into best practices for managing breakthrough cancer pain among oncology nurses across Europe.
A global survey of people living with HIV/AIDS found a significant gap in patient-physician dialogue, with discussions often lacking on chronic illnesses, treatment side effects, and co-morbid conditions. Co-morbidities like cardiovascular disease, high cholesterol, and hepatitis C are prevalent among PLWHA.
A European survey found that up to 45% of cancer patients with breakthrough pain do not adhere to medication despite severe episodes. Patients want medications that relieve pain quickly and cause few side effects, yet current treatments often fail to meet these needs.
A new survey of 4,000 American adults reveals that fewer than one-third have been vaccinated against the flu, citing misperceptions and lack of time as main reasons. The CDC's National Influenza Vaccination Week aims to encourage greater use of influenza vaccines through December.
The US FDA has approved KINRIX, a combination vaccine that protects against four serious diseases: diphtheria, tetanus, pertussis and polio. Clinical studies show similar protection to separately administered vaccines with a comparable safety profile.
Data presented at the APA Annual Meeting demonstrate iloperidone's efficacy and safety in treating schizophrenia, with low rates of movement disorders and metabolic adverse events. Pharmacogenetic findings suggest potential for individualized treatment based on genetic markers.
Results from two Phase I trials demonstrate clinical activity of ZOLINZA (vorinostat) combined with bortezomib in patients with relapsed and/or refractory multiple myeloma. The combination treatment showed partial or minimal responses in 48% of evaluable patients, suggesting potential for further evaluation in randomized clinical trials.
The report estimates that nearly 60% of people with type 2 diabetes have at least one serious health complication, including heart disease, stroke, and chronic kidney disease. Estimated annual healthcare costs for a person with type 2 diabetes complications exceed $10,000.
New data demonstrate that lamotrigine is an effective adjunctive therapy for treating primary generalized tonic-clonic (PGTC) seizures in children and adolescents. The study found a significant reduction in PGTC seizure counts among patients receiving lamotrigine, with a median percent decrease of 77% compared to the placebo group.
Researchers found five predictors associated with bipolar disorder risk: people were unfriendly, co-morbid anxiety, depression diagnosis within five years, family history of bipolar disorder, and legal problems. These findings may help physicians better assess a patient's risk for bipolar disorder.
A new analysis reveals that combination vaccines significantly increased on-time immunization rates in infants. The study found that the combination group had a 42.7% on-time rate for the HEDIS Combo 2 series, compared to 34.9% in the component group.
The study found that combination vaccine groups had significantly higher coverage rates for various vaccines, including DTaP, polio, and hepatitis B. Additionally, children in the combination cohort received their vaccinations on time more frequently than those in the component cohort.
The rotavirus vaccine candidate demonstrated 85% protection against severe disease and 100% protection against more severe disease in a double-blind, placebo-controlled trial. The vaccine also showed lower incidence of serious adverse events compared to placebo, with no increased risk of intussusception observed.
A new Israeli study found that vaccinating all children against hepatitis A at 18 and 24 months reduced overall incidence of the disease for all ages by 95%. The study also showed a significant decrease in reported incidents among one- to four-year-olds, a demographic historically susceptible to infection.
The study found that 7.2% of the general population reported RLS symptoms, with women experiencing twice as high frequency of symptoms as men. Quality of life was significantly impacted, with RLS sufferers reporting lower scores than the general population.
Boostrix is approved by the FDA for use in US adolescents against pertussis, with reported cases rising nearly 20-fold since 1976. Experts estimate the true incidence of the disease may be greater than one million cases per year, particularly among teens.
A study shows that lidocaine patch 5% and celecoxib achieved significant reductions in pain intensity, with 62% of patients in the celecoxib group experiencing a 30% or greater improvement. The findings offer hope for OA patients seeking alternative pain relief options.
A head-to-head study comparing Lidoderm patches and Celebrex found that Lidoderm alleviated knee pain in 54% of patients, while Celebrex showed similar results in 62%. The study's findings are promising for further research into Lidoderm's potential as an osteoarthritis treatment.
The Society for Adolescent Medicine advocates for adolescents to receive extended protection against pertussis. Adding a pertussis component to the current tetanus-diphtheria booster vaccine could help prevent this disease in teens and reduce transmission to infants.
The FDA Advisory Committee has unanimously recommended approval of Boostrix, a vaccine candidate against pertussis, for use in adolescents. The vaccine showed comparable safety and immunogenicity to a U.S.-licensed Td vaccine, with higher anti-pertussis antibody levels in adolescents than in infants.
A study shows Requip significantly improves symptoms of primary RLS, including improvements in sleep and quality of life. Patients treated with Requip experienced greater improvements compared to those taking placebo.
A recent survey found that asthma control in US children falls short of national treatment goals, with most experiencing frequent symptoms and missed school days. The study highlights the need for better communication between parents and children to effectively manage the condition.
A new pertussis booster vaccine candidate has shown promising results in a clinical trial, providing extended protection against whooping cough, diphtheria, and tetanus for adolescents. The vaccine, Boostrix, demonstrated high levels of anti-pertussis antibodies and comparable side effects to the existing Td vaccine.
DepoDur offers a safe and effective alternative to traditional epidural analgesia, providing up to 48 hours of effective pain control without the need for continuous infusion. This single-shot epidural formulation has been shown to improve treatment of postoperative pain following major surgery.
A study of postmenopausal women found that nearly half had vitamin D levels below the threshold, highlighting the importance of adequate supplementation and proper exposure to sunlight. Vitamin D plays a crucial role in osteoporosis management by promoting calcium absorption and resorption.
The survey found that despite parents' awareness of hepatitis B, many are unaware of the disease's severity and the availability of a vaccine. The Society for Adolescent Medicine provides guidance to enhance parent-adolescent relationships and offers resources to promote healthy behaviors.
A survey of mothers reveals that they view pediatricians as 'parenting partners' and carefully select a doctor for their child. Key findings include the importance of personality, health insurance coverage, and compatibility with parenting objectives in choosing a pediatrician.
A study found that Requip significantly reduced Periodic Leg Movements (PLMS) in patients with Restless Legs Syndrome (RLS), leading to improved sleep latency and fewer awakenings. The medication also effectively reduced PLMS to normal levels for more than half of the patients.
The BCIRG 001 trial showed a significant reduction in recurrence of disease in hormone-receptor-positive and negative patients with a Taxotere-based treatment, improving disease-free survival by 28% and overall survival by 30%. The regimen demonstrated effectiveness across various stages of breast cancer.
A multi-center study found improved overall survival and time to disease progression for women with metastatic breast cancer treated with Taxotere, compared to paclitaxel. The results suggest that Taxotere may be a more effective treatment option for this patient population.
A comparative study found Factive eradicated H. influenzae after one day, while Biaxin took seven days. The results showed Factive's superior efficacy in treating chronic bronchitis airway infections.
The COPERNICUS trial demonstrates a significant survival benefit of carvedilol in patients with advanced heart failure, reducing mortality rates by 35%. The study involved over 2,200 patients and showed that carvedilol decreased mortality rates compared to placebo.
Researchers found that Avandia improves beta cell function, as measured by proinsulin to insulin ratio, indicating potential benefits for long-term glycemic control and disease progression. The study's results support the use of Avandia in type 2 diabetes treatment and suggest its potential to delay disease progression.
A study published in The New England Journal of Medicine confirms Requip's efficacy in managing early Parkinson's disease symptoms with a low risk of developing dyskinesias. Patients taking Requip alone were seven times more likely to remain dyskinesia-free than those on levodopa alone.